Vabysmo 6 MG/0.05 ML syringe 0.05ML
Ended Awarded Last action
- Contract number
- SPE2DR26FCRM3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,179
Award facts
- Contract value 100% obligated
- $12,179.12 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency has awarded a delivery order valued at approximately $12.2K to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Vabysmo 6 mg/0.05 mL syringes. This firm fixed-price delivery order, issued on December 4, 2025, with an ultimate completion date of December 26, 2025, was issued without set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group was selected as the awardee based on its established performance as a critical supplier within the federal pharmaceutical supply chain, particularly to the Department of Defense.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR. That underlying contract, awarded on November 13, 2025, carries a ceiling value of $499.9M with a completion date of December 31, 2036, positioning DMS Pharmaceutical Group as one of multiple regional prime vendor contractors supporting the Department of Defense's $30.3 billion pharmaceutical supply chain strategy. The PPV-G GEN V contract authorizes DLA to issue firm fixed-price delivery orders for comprehensive pharmaceutical products and medical consumables to support military healthcare facilities worldwide, enabling DMS Pharmaceutical Group to serve as a critical pharmaceutical supplier for DoD operations globally.
Quick answers
Who was awarded contract SPE2DR26FCRM3?
SPE2DR26FCRM3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 4, 2025.
How much is contract SPE2DR26FCRM3 worth?
The government has obligated $12,179 on SPE2DR26FCRM3.
Is contract SPE2DR26FCRM3 an order under another contract?
Yes. SPE2DR26FCRM3 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRM3 competed?
The extent of competition for SPE2DR26FCRM3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award